Mobia Medical, Inc. (NASDAQ:MOBI) Stock Has Consensus Price Target of $20.75 According to Analysts

Key Points

• Analyst sentiment is moderately bullish: Seven analysts rate Mobia Medical “Moderate Buy,” with five buys, one hold, and one sell. The average 12-month price target is $20.75, compared with the stock’s recent price of $11.27.
• Insiders have been buying shares: Director Casey Tansey purchased 35,572 shares for approximately $409,000, while insiders bought 87,000 shares worth about $1.02 million over the past quarter.
• Revenue growth was strong but profitability missed expectations: Quarterly revenue rose 102.4% year over year to $13.51 million, but the company reported an adjusted loss of $1.10 per share versus the $0.83 consensus estimate.

Shares of Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $20.75.

Several equities analysts have recently issued reports on the company. Weiss Ratings started coverage on Mobia Medical in a report on Wednesday, August 12th. They issued a "sell (e-)" rating for the company. BTIG Research reiterated a "buy" rating and set a $19.00 price target on shares of Mobia Medical in a report on Tuesday, October 20th. Finally, JPMorgan Chase & Co. boosted their price objective on Mobia Medical from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th.

Insider Buying and Selling at Mobia Medical

In related news, Director Casey Tansey purchased 35,572 shares of Mobia Medical stock in a transaction that occurred on Thursday, August 13th. The stock was bought at an average price of $11.51 per share, for a total transaction of $409,433.72. Following the completion of the transaction, the director owned 268,904 shares in the company, valued at $3,095,085.04. This represents a 15.25% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have bought 87,000 shares of company stock valued at $1,016,367.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp purchased a new stake in shares of Mobia Medical during the 2nd quarter worth approximately $735,000. Citadel Advisors LLC bought a new stake in shares of Mobia Medical in the 2nd quarter worth approximately $670,000. Finally, Readystate Asset Management LP purchased a new position in Mobia Medical in the second quarter valued at approximately $134,000.

Mobia Medical Price Performance

MOBI opened at $11.27 on Friday. Mobia Medical has a fifty-two week low of $8.03 and a fifty-two week high of $15.29. The company has a market capitalization of $375.18 million and a price-to-earnings ratio of -0.56. The firm's 50-day moving average price is $10.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80.

Mobia Medical (NASDAQ:MOBI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. Mobia Medical's revenue was up 102.4% on a year-over-year basis. On average, equities research analysts expect that Mobia Medical will post -2.63 earnings per share for the current year.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.